Pfizer says its booster shot has 95.6% efficacy against Covid-19 amid the Delta variant
- Pfizer said its booster shot is 95.6% effective against preventing Covid-19 amid the Delta variant.
- The results were from its first large trial, of more than 10,000 people aged 16 and older.
- Half of the participants got the third booster dose, and half got a placebo.
- For more stories visit Business Insider.
Pfizer said on Monday that its coronavirus booster shot has 95.6% efficacy at preventing Covid-19 amid the Delta variant.
The results were from a randomised, controlled Phase 3 trial of the booster dose in more than 10,000 individuals aged 16 or older
Pfizer Chairman and CEO Albert Bourla said in the statement: "These results provide further evidence of the benefits of boosters as we aim to keep people well-protected against this disease."
All participants in the trial had already recieved two doses of the Pfizer/BioNTech vaccine. Half of them then got the third booster dose, and half got a placebo.
Get the best of our site emailed to you every weekday.
Go to the Business Insider front page for more stories.